SCHEMBL3752705

SCHEMBL3752705

CC(C)(C)OC(=O)c1ccc(NC(=O)OCc2ccccc2)cc1F

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 3/20 0.51
SMN1; SMN2 Q16637 2/20 0.49
TP53 P04637 2/20 0.49
MAPT P10636 2/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
ALDH1A1 P00352 1/20 0.49
TSHR P16473 1/20 0.49
ATM Q13315 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
PTGDR2 Q9Y5Y4 1/20 0.48
POLB P06746 1/20 0.47
ENPP2 Q13822 2/20 0.46
ROCK2 O75116 1/20 0.46
PTPN1 P18031 1/20 0.44
SYK P43405 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3758290 0.85 MGLL (0.60) MGLLSMN1; SMN2TP53MAPTNPC1
SCHEMBL13193091 0.84 MGLL (0.51) MGLLSMN1; SMN2TP53MAPTNPC1
SCHEMBL6099091 0.82 TSHR (0.59) MGLLSMN1; SMN2TP53MAPTNPC1
SCHEMBL2409894 0.81 RAB9A (0.59) MGLLSMN1; SMN2TP53MAPTNPC1
SCHEMBL7043026 0.80 POLB (0.62) MGLLSMN1; SMN2TP53MAPTNPC1
SCHEMBL7595080 0.80 MGLL (0.49) MGLLSMN1; SMN2TP53MAPTNPC1
SCHEMBL591401 0.79 MGLL (0.59) MGLLSMN1; SMN2TP53MAPTNPC1
SCHEMBL6607338 0.79 SMN1; SMN2 (0.47) MGLLSMN1; SMN2TP53MAPTNPC1
SCHEMBL7400180 0.79 MGLL (0.50) MGLLSMN1; SMN2TP53MAPTNPC1
SCHEMBL15055245 0.78 RAB9A (0.54) MGLLSMN1; SMN2TP53MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298384-A1 NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS DR. REDDY'S LABORATORIES LTD. (IN) 2010-11-25 US disclosed
US-20100298384-A1 NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS DR. REDDY'S LABORATORIES LTD. (IN) 2010-11-25 US disclosed
WO-2008143649-A2 NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS DR. REDDY'S LABORATORIES LIMITED (IN) 2008-11-27 WO disclosed
WO-2008143649-A2 NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS DR. REDDY'S LABORATORIES LIMITED (IN) 2008-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298384-A1 NOVEL OXAZOLIDINONE COMPOUNDS AS ANTIINFECTIVE AGENTS OXA1L, MIF, VIP MGLL 1065/4885SMN1; SMN2 2861/4885TP53 3525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.